BHT-3021 Gottlieb EASD 2008 poster
Interim Results of a Phase I/II Clinical Trial of a DNA Plasmid Vaccine (BHT-3021) for Type 1 Diabetes
link to PDF




DNA Vaccines Forum 2008
March 10 – 11th, 2008
London, UK
Studying the Effects of Using an Antigen Specific DNA Plasmid to Treat Multiple Sclerosis

MVAF
Nov 12 – 14, 2007
Dublin, Ireland
DNA vaccines for autoimmune diseases: results from a phase IIb clinical trial of a DNA plasmid (BHT-3009) for multiple sclerosis, and interim results of a phase I/II clinical trial of a DNA plasmid (BHT-3021) for type 1 diabetes

5th International Conference on Vaccines: All Things Considered
November 7 – 9, 2007
Washington, DC
DNA Vaccines for Autoimmune Disease: Clinical Experience




23rd Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS)
12th Annual Conference of Rehabilitation in MS (RIMS)
Oct 11 – 14, 2007
Prague, Czh.
Phase IIb Trial of a MBP Encoding DNA Plasmid (BHT-3009) for the Treatment of Relapsing Remitting Multiple Sclerosis
16. Therapy disease modifying – Immunomodulation




American Neurological Association 132nd Annual Meeting
October 7th – 10th, 2007
Washington, DC
Phase IIb Trial of BHT-3009 for the Treatment of Relapsing-Remitting Multiple Sclerosis




7th Annual Meeting
FOCIS – Federation of Clinical Immunology Societies
June 7-11, 2007
San Diego, California
Antigen Specific Immune Modulation




DNA Vaccines 2007
The Gene Vaccine Conference
May 23-25
Torrequebrada Hotel, Malaga, Spain
DNA vaccine for autoimmune diseases: results from a phase I/II clinical trial of a plasmid (BHT-3009) for multiple sclerosis and interim results of a phase I/II clinical trial of a DNA plasmid (BHT-3021) for type 1 diabetes

The 11th International Conference on Myasthenia Gravis and Related Disorders
May 13 – 16, 2007
Chicago, IL
A DNA vaccine encoding the acetylcholine receptor treats the EAMG model of MG




“Phase I/II trial of a MBP encoding DNA plasmid (BHT-3009) alone or combined with atorvastatin for treatment of MS”
Poster number PP14-22 presented at the 8th International Congress of Neuroimmunology, Nagoya, Japan, October 15-19, 2006




MVADS
Sept 12 – 14, 2006
London, England
DNA vaccines for autoimmune disease: results from a phase I/II clinical trial of a DNA plasmid (BHT-3009) for multiple sclerosis and pre-clinical results of a DNA plasmid (BHT-3021) for type 1 diabetes.




Scientific Program: Pathogeniesis of Rare Neuroimmunologic Disorders 2006
July 20 – 22, 2006
Baltimore, MD
Antigen specific immunotherapies in clinical trials




American Diabetes Association 66th Scientific Sessions, 2006
June 9th – 13th
Washington, DC
A proinsulin encoding DNA plasmid vaccine decreases cellular and humoral autoimmune response to insulin and response to insulin, and reverses established hyperglycemia in NOD mice

BHT-3021 ADA 2006 poster
A proinsulin encoding DNA plasmid vaccine decreases cellular and humoral autoimmune response to insulin and reverses established hyperglycemia in NOD mice
link to PDF




Antigen-specific immunomodulation in multiple sclerosis patients treated with MBP encoding DNA plasmid (BHT-3009) alone or combined with atorvastatin
September 28 – October 1, 2005
Poster presented at 21st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Thessaloniki, Greece